DK1411926T3 - Integrininhibitorer til behandling af öjensygdomme - Google Patents
Integrininhibitorer til behandling af öjensygdommeInfo
- Publication number
- DK1411926T3 DK1411926T3 DK02748841T DK02748841T DK1411926T3 DK 1411926 T3 DK1411926 T3 DK 1411926T3 DK 02748841 T DK02748841 T DK 02748841T DK 02748841 T DK02748841 T DK 02748841T DK 1411926 T3 DK1411926 T3 DK 1411926T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- eye diseases
- integrin inhibitors
- integrin
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30885101P | 2001-08-01 | 2001-08-01 | |
PCT/EP2002/007377 WO2003013511A1 (en) | 2001-08-01 | 2002-07-03 | Integrin inhibitors for the treatment of eye diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1411926T3 true DK1411926T3 (da) | 2005-08-29 |
Family
ID=23195644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02748841T DK1411926T3 (da) | 2001-08-01 | 2002-07-03 | Integrininhibitorer til behandling af öjensygdomme |
Country Status (20)
Country | Link |
---|---|
US (2) | US20040198644A1 (ru) |
EP (1) | EP1411926B1 (ru) |
JP (1) | JP2005504757A (ru) |
KR (1) | KR20040028966A (ru) |
CN (1) | CN1536998A (ru) |
AR (1) | AR036199A1 (ru) |
AT (1) | ATE296628T1 (ru) |
AU (1) | AU2002319282B2 (ru) |
BR (1) | BR0211604A (ru) |
CA (1) | CA2456076C (ru) |
DE (1) | DE60204466T2 (ru) |
DK (1) | DK1411926T3 (ru) |
ES (1) | ES2243744T3 (ru) |
HU (1) | HUP0401605A3 (ru) |
MX (1) | MXPA04000839A (ru) |
PL (1) | PL207175B1 (ru) |
PT (1) | PT1411926E (ru) |
RU (1) | RU2311177C2 (ru) |
WO (1) | WO2003013511A1 (ru) |
ZA (1) | ZA200401598B (ru) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8236352B2 (en) | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
US7198795B2 (en) * | 2000-09-21 | 2007-04-03 | Elan Pharma International Ltd. | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions |
ATE464880T1 (de) | 2002-02-04 | 2010-05-15 | Elan Pharma Int Ltd | Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator |
CA2605587A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Chromane and chromene derivatives and uses thereof |
CA2705916C (en) | 2007-11-16 | 2016-01-05 | Ube Industries, Ltd. | Benzazepinone compound |
US20120095215A1 (en) | 2009-03-30 | 2012-04-19 | Ube Industries, Ltd. | Medical composition for treatment or prophylaxis of eye diseases |
WO2011106702A2 (en) | 2010-02-25 | 2011-09-01 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
US9327037B2 (en) | 2011-02-08 | 2016-05-03 | The Johns Hopkins University | Mucus penetrating gene carriers |
EP2825207B1 (en) | 2012-03-16 | 2020-08-19 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
JP5883539B2 (ja) | 2012-03-16 | 2016-03-15 | ザ・ジョンズ・ホプキンス・ユニバーシティー | Hif−1阻害剤の送達のための放出制御製剤 |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
US9533068B2 (en) | 2012-05-04 | 2017-01-03 | The Johns Hopkins University | Drug loaded microfiber sutures for ophthalmic application |
US20150119792A1 (en) * | 2012-05-08 | 2015-04-30 | The Regents Of The University Of California | Light degradable drug delivery system for ocular therapy |
WO2014124006A1 (en) | 2013-02-05 | 2014-08-14 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
US9394285B2 (en) | 2013-03-15 | 2016-07-19 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
AU2016211696B2 (en) | 2015-01-27 | 2018-05-10 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
KR101748120B1 (ko) * | 2015-07-13 | 2017-06-16 | 서울대학교산학협력단 | 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도 |
CN108291199A (zh) * | 2015-12-04 | 2018-07-17 | 詹森生物科技公司 | 使用祖细胞治疗视网膜变性 |
US10745384B2 (en) * | 2016-11-08 | 2020-08-18 | Bristol-Myers Squibb Company | Indazole derivatives as αv integrin antagonists |
KR102307767B1 (ko) * | 2019-03-11 | 2021-10-01 | 서울대학교병원 | 망막맥락막 신생혈관성 질환을 진단하기 위한 인테그린 αvβ3 표적화 프로브 및 이의 제조 방법 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69635417T2 (de) * | 1995-08-14 | 2006-07-13 | The Scripps Research Institute, La Jolla | VERFAHREN UND MITTEL ZUR HEMMUNG DER DURCH ALPHA v BETA 5 VERMITTELTEN ANGIOGENESE |
DE19538741A1 (de) * | 1995-10-18 | 1997-04-24 | Merck Patent Gmbh | Cyclopeptidderivate |
US5904144A (en) * | 1996-03-22 | 1999-05-18 | Cytotherapeutics, Inc. | Method for treating ophthalmic diseases |
AU733303C (en) * | 1996-05-31 | 2002-08-08 | Scripps Research Institute, The | Methods and compositions useful for inhibition of angiogenesis |
BR9709514A (pt) * | 1996-05-31 | 1999-08-10 | Scripps Research Inst | Processo e composições úteis para a inibição de angiogénese mediada por alfa beta |
DE19705450A1 (de) * | 1997-02-13 | 1998-08-20 | Merck Patent Gmbh | Bicyclische aromatische Aminosäuren |
US6255353B1 (en) * | 1998-03-13 | 2001-07-03 | Centaur Pharmaceuticals, Inc. | Inhibition of angiogenesis |
US6489305B1 (en) * | 1998-05-08 | 2002-12-03 | Canji, Inc. | Methods and compositions for the treatment of ocular diseases |
US6378526B1 (en) * | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
DE19850131A1 (de) * | 1998-10-30 | 2000-05-04 | Merck Patent Gmbh | Chromenon- und Chromanonderivate |
DE10006139A1 (de) * | 2000-02-11 | 2001-08-16 | Merck Patent Gmbh | Indol-3-yl-Derivate |
-
2002
- 2002-07-03 HU HU0401605A patent/HUP0401605A3/hu unknown
- 2002-07-03 DK DK02748841T patent/DK1411926T3/da active
- 2002-07-03 MX MXPA04000839A patent/MXPA04000839A/es unknown
- 2002-07-03 US US10/485,386 patent/US20040198644A1/en not_active Abandoned
- 2002-07-03 ES ES02748841T patent/ES2243744T3/es not_active Expired - Lifetime
- 2002-07-03 CA CA2456076A patent/CA2456076C/en not_active Expired - Fee Related
- 2002-07-03 AU AU2002319282A patent/AU2002319282B2/en not_active Ceased
- 2002-07-03 BR BR0211604-9A patent/BR0211604A/pt not_active IP Right Cessation
- 2002-07-03 KR KR10-2004-7001509A patent/KR20040028966A/ko not_active Application Discontinuation
- 2002-07-03 WO PCT/EP2002/007377 patent/WO2003013511A1/en active IP Right Grant
- 2002-07-03 PL PL367959A patent/PL207175B1/pl not_active IP Right Cessation
- 2002-07-03 PT PT02748841T patent/PT1411926E/pt unknown
- 2002-07-03 EP EP02748841A patent/EP1411926B1/en not_active Expired - Lifetime
- 2002-07-03 CN CNA028151038A patent/CN1536998A/zh active Pending
- 2002-07-03 DE DE60204466T patent/DE60204466T2/de not_active Expired - Lifetime
- 2002-07-03 JP JP2003518520A patent/JP2005504757A/ja active Pending
- 2002-07-03 RU RU2004106527/14A patent/RU2311177C2/ru not_active IP Right Cessation
- 2002-07-03 AT AT02748841T patent/ATE296628T1/de active
- 2002-07-31 AR ARP020102892A patent/AR036199A1/es not_active Application Discontinuation
-
2004
- 2004-02-26 ZA ZA200401598A patent/ZA200401598B/en unknown
-
2006
- 2006-08-28 US US11/510,596 patent/US7645736B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2003013511A1 (en) | 2003-02-20 |
ZA200401598B (en) | 2004-11-17 |
US20040198644A1 (en) | 2004-10-07 |
EP1411926A1 (en) | 2004-04-28 |
AR036199A1 (es) | 2004-08-18 |
ES2243744T3 (es) | 2005-12-01 |
PL367959A1 (en) | 2005-03-07 |
EP1411926B1 (en) | 2005-06-01 |
JP2005504757A (ja) | 2005-02-17 |
AU2002319282B2 (en) | 2007-06-28 |
US7645736B2 (en) | 2010-01-12 |
MXPA04000839A (es) | 2004-05-14 |
CA2456076C (en) | 2011-08-23 |
HUP0401605A3 (en) | 2012-09-28 |
CA2456076A1 (en) | 2003-02-20 |
DE60204466T2 (de) | 2006-04-27 |
US20060287225A1 (en) | 2006-12-21 |
CN1536998A (zh) | 2004-10-13 |
DE60204466D1 (de) | 2005-07-07 |
PT1411926E (pt) | 2005-10-31 |
ATE296628T1 (de) | 2005-06-15 |
BR0211604A (pt) | 2004-08-24 |
PL207175B1 (pl) | 2010-11-30 |
RU2004106527A (ru) | 2005-07-10 |
HUP0401605A2 (hu) | 2004-11-29 |
KR20040028966A (ko) | 2004-04-03 |
RU2311177C2 (ru) | 2007-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1411926T3 (da) | Integrininhibitorer til behandling af öjensygdomme | |
DK1575597T3 (da) | Anvendelse af rimexolon til behandling af öjentörhed | |
IS7215A (is) | Aðferðir til að meðhöndla nýæðarsjúkdóma í augum | |
DK1944322T3 (da) | Behandling af TNFalfa-relaterede sygdomme | |
DK1446122T3 (da) | Anvendelse af flibanserin til behandling af uregelmæssigheder ved könsdriften | |
DK2308507T3 (da) | Fremgangsmåder til behandling af præeklampsi | |
DK1803718T3 (da) | 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter | |
DK1762567T3 (da) | Pyrazolderivater til behandling af HIV | |
NO20035609D0 (no) | Fremgangsmåte for kontinuerlig naftabehandling | |
DK1509121T3 (da) | Okulærvisningsapparat til behandling af øjenlidelser | |
NO20035156D0 (no) | Fremgangsmåter for brönnbehandling | |
DK1343773T3 (da) | Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser | |
DK1448205T3 (da) | Kombinationer til behandling af immunoinflammatoriske sygdomme | |
DK1392318T3 (da) | 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse | |
NO20035224D0 (no) | Oftalmisk pirenzepingel | |
DK1516596T3 (da) | Forbedret system til behandling af stress-urinkontinens | |
DK1381382T3 (da) | Fremgangsmåder og præparater til behandling af öjensygdomme | |
NO20034123L (no) | Fremgangsmåte for behandling av brennstoff | |
DK1727801T3 (da) | Til behandling af smerter anvendelige piperaziner | |
DE60200302D1 (de) | Laseraugenbehandlungseinrichtung | |
DK1268482T3 (da) | Pyranoindoler til behandling af glaukom | |
NO20042613L (no) | Ny anvendelse for behandling av gastroosofagial refluks | |
DK1309322T3 (da) | Anvendelse af 3-benzoylphenyleddikesyrederivater til behandling af retinale lidelser | |
DK1400522T3 (da) | Forbindelser til behandling af impotens | |
DK1289945T3 (da) | Anilindisulfidderivater til behandling af allergiske sygdomme |